Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. NVDA
6. WMT
7. SPY
8. RXST
9. RIVN
10. LMT

Go back to Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) PT Raised to $28 at SunTrust Robinson Humphrey; 'Adding Back Bipolar Depression'

March 2, 2018 9:03 AM EST

SunTrust Robinson Humphrey raised its price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $28.00 (from $22.00) while maintaining a Buy rating.

Analyst Edward Nash commented, "Intra-Cellular will have a pre-NDA meeting with the FDA in 1Q18 for lumateperone for schizophrenia. Company expects to file NDA for... More